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Abstract
Background: Secretoglobin (SCGB) 3A1 is a secretory protein of small molecular weight with
tumor suppressor function. It is highly expressed in lung and trachea in both human and mouse,
with additional tissues expressing the protein that differ depending on the species. However, little
is known about the function and transcriptional regulation of this gene in normal mouse tissues.
Results: By reporter gene transfection and gel mobility shift analyses, we demonstrated that
expression of the mouse Scgb3a1 gene is regulated by a PU-box binding protein and a ubiquitous
transcription factor NF-Y that respectively binds to the PU-boxes located at -99 to -105 bp and -
158 to -164 bp, and the "CCAAT" binding sites located at -425 to -429 bp and -498 to -502 bp from
the transcription start site of the gene. However, the effect of PU-box binding protein on
transcriptional activation is minimal as compared to NF-Y, suggesting that NF-Y is a more critical
transcription factor for mouse Scgb3a1 gene transcription. Despite that NF-Y is a ubiquitous factor,
Scgb3a1 is highly expressed only in mouse lung and mtCC cells that are derived from SV40
transformed mouse Clara cells, but not in ten other mouse tissues/cells examined. Gene
methylation analysis revealed that within 600 bp of the Scgb3a1 gene promoter region, there are
nine CpG methylation sites present, of which two CpGs closest to the transcription start site of
the gene are unmethylated in the tissues/cells expressing SCGB3A1.
Conclusion: A ubiquitous transcription factor NF-Y binds to and activates expression of the
mouse Scgb3a1 gene and tissue-specific expression of the gene is associated with CpG methylation
of the promoter.
Background
Secretoglobin (SCGB) 3A1, also called high in normal-1
(HIN-1) [1] or uteroglobin-related protein 2 (UGRP2)
[2], is a member of the SCGB gene superfamily that con-
sists of small secretory proteins [3]. HIN-1 was originally
identified as a tumor suppressor gene because its expres-
sion was silenced by methylation in the majority of
human breast carcinomas [1]. UGRP2 was independently
identified as a homologous gene to UGRP1 (also called
SCGB3A2) that is a downstream target for the homeodo-
main transcription factor NKX2-1, also called TITF1, TTF1,
NKX2.1, or T/EBP [2]. Mouse SCGB3A1 and SCGB3A2
share 33% amino acid sequence identity [2].
In humans, SCGB3A1 is highly expressed in the trachea,
lung, salivary gland, prostate, esophagus, duodenum and
mammary gland [1,2,4], whereas in mouse, it is primarily
expressed in the trachea and lung, and weakly expressed in
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the heart, stomach, and small intestine [2,4,5]. Methyla-
tion patterns of the human SCGB3A1 gene promoter have
been extensively studied and a correlation of methylation
and loss of SCGB3A1 expression and malignant pheno-
types is well established in many human cancers includ-
ing breast, prostate, lung, and pancreatic carcinomas [6-
8]. The AKT signaling pathway is responsible for the
SCGB3A1's tumor suppressor function as characterized by
inhibition of cell growth, cell migration and invasion [9].
In this connection, it was shown that EGF and TGFγ
increase SCGB3A1 expression through activation of the
ERK-MAPK and phosphoinositide-3 kinase-AKT pathways
[10]. Further, the expression of SCGB3A1 is restricted to
terminally differentiated airway epithelial cells and is up-
regulated during retinoic acid induced differentiation of
bronchial epithelial cells, suggesting that SCGB3A1 may
be involved in the acquisition or maintenance of the ter-
minally differentiated epithelial phenotype [5].
Under interleukin (IL)-4 and IL-13 stimulation, SCGB3A1
expression is up-regulated through binding of STAT6 to
the STAT binding element located in -201 to -209 bp of
the mouse Scgb3a1 gene promoter [11], suggesting that
SCGB3A1 may also play a role in inflammation. In fact, a
recent report demonstrated that SCGB3A2 (UGRP1), a
homologous gene to SCGB3A1, suppresses allergic airway
inflammation when a mouse model for allergic airway
inflammation is subjected to intranasal administration of
recombinant adenovirus expressing SCGB3A2 [12].
STAT6 is the only transcription factor downstream of IL-4
and IL-13 signaling thus far demonstrated that directly
binds to the Scgb3a1 promoter and regulates expression of
the gene [11]. It is not known what transcription factors
are involved in constitutive expression of the mouse
Scgb3a1.
In this study, we demonstrate that a ubiquitous transcrip-
tion factor NF-Y is an important transcription factor for
controlling expression of the mouse Scgb3a1 gene through
its binding to the responsive "CCAAT" element located at
-425 to -429, and -498 to -502 bp upstream of the Scgb3a1
gene. The methylation pattern of the mouse Scgb3a1 gene
is examined and the association of the two closest CpGs
to the transcription start site in tissue-specific expression
of the mouse Scgb3a1 gene is discussed.
Results
Analysis of the mouse Scgb3a1 gene promoter
In an attempt to understand the mechanism of mouse
Scgb3a1 gene expression, we first compared the promoter
sequence of the mouse Scgb3a1  gene with the human
SCGB3A1  gene. Interestingly, no significant homology
was found by BLAST analysis when 2-kbp mouse Scgb3a1
gene promoter sequence was subjected to analysis, sug-
gesting that the regulation of human and mouse Scgb3a1
genes may be quite different. Six mouse Scgb3a1 gene pro-
moter-luciferase reporter constructs (pGL4, -59, -91, -184,
-273, and -598) were then prepared and subjected to tran-
sient transfection analysis using transformed mouse Clara
cells (mtCC) that are derived from tumor tissues of lungs
obtained from transgenic mice expressing the simian virus
40 large T antigen gene under control of uteroglobin/
Clara cell secretory protein promoter [13]. The reporter
activity slightly increased with construct -91 (Fig. 1A). An
approximately ten-fold enhancement of promoter activity
as compared to a control construct pGL4 was obtained
with the -184 construct, and the extent of activity
remained at similar levels up to -273 bp of the promoter
sequence. A further robust up-regulation (~25-fold) of the
promoter activity as compared to control was obtained
with construct -598, suggesting that transcriptional
response elements may be present between -91 and -184
bp, and -273 and -598 bp of the mouse Scgb3a1 gene pro-
moter. Possible binding sites for transcription factors were
analyzed using the TF search [14], TRANSFAC [15] and
the reference of [16]. The analysis revealed the presence of
two PU boxes (5'-AGAGGAA-3') between -91 and -184 bp
and two NF-Y binding sites (5'-CCAAT-3') between -273
and -598 bp that may be responsible for up-regulation of
Scgb3a1 gene expression (Fig. 1B). The PU-box is a bind-
ing site for the ETS family of transcription factors that par-
ticipate in an array of cellular activities in development,
differentiation and tumorigenesis, and is a main regulator
of the immune system [17,18]. NF-Y is a ubiquitous het-
erotrimeric transcription factor, composed of NF-YA, NF-
YB, and NF-YC, all of which are necessary for DNA bind-
ing, and recognizes "CCAAT" penta-nucleotide element
[19-22]. A STAT binding site (-201 to -209 bp) that we
previously characterized [11] for IL-4/13-induced increase
of SCGB3A1 expression did not seem to be involved in the
constitutive expression of SCGB3A1. Further TF search
analysis with low stringency revealed a possible binding
site for GATA (-11 to -20 bp and -132 to -141 bp), C/EBP
(-61 to -72 bp) and HNF3β (-64 to -76 bp), transcription
factors known to be involved in lung-specific gene expres-
sion [23]; the latter two might contribute a slight increase
of the reporter activity found with the -91 construct.
NF-Y is involved in the mouse Scgb3a1 gene transcription
The involvement of NF-Y in mouse Scgb3a1 gene tran-
scription was first examined by co-transfecting pGL4 con-
trol vector, -59, -273, and -598 Scgb3a1-luciferase
constructs with expression plasmids for three NF-Y subu-
nits into COS-1 cells that do not express SCGB3A1 (Fig.
2A). Only construct -598 has putative NF-Y binding sites.
Luciferase activity increased approximately two-fold with
the constructs -59 and -273. Further inclusion of upstream
sequence up to -598 bp markedly increased luciferase
activity to almost twenty-fold as compared to control,
confirming the involvement of NF-Y in mouse Scgb3a1BMC Molecular Biology 2008, 9:5 http://www.biomedcentral.com/1471-2199/9/5
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gene transcription. In order to examine whether all three
NF-Y subunits are required for expression of SCGB3A1,
co-transfecting analysis was carried out using single or a
various combinations of NF-Y subunits (Fig. 2B). The
results clearly demonstrate that all three NF-Y subunits are
required for Scgb3a1  gene transcription as previously
described [21]. Further, replacing the NF-YA construct
with NF-YAm29, a dominant negative form of NF-YA that
lacks the DNA binding activity due to displacement of
three critical amino acids in the middle of the DNA bind-
ing domain but retaining the ability to form the NF-Y het-
erotrimer [24], NF-Y up-regulation of -598 luciferase
activity was reduced to close to basal levels, suggesting
that the NF-YA subunit is critical for transcriptional activa-
tion (Fig. 2A). These results demonstrate that NF-Y may
activate mouse Scgb3a1 transcription by binding to the
NF-Y binding site(s) located between -273 and -598 bp of
the Scgb3a1 gene promoter.
In the -273 to -598 bp region, two "CCAAT" sequences are
present at -425 to -429 bp and -498 to -502 bp (reverse
direction) from the transcription start site (Fig. 1B). In
order to determine which putative binding sites are
involved in binding of NF-Y that is responsible for the
increase of Scgb3a1  gene promoter activity, electro-
phoretic gel mobility shift analysis (EMSA) was carried
out using double strand oligonucleotides containing
proximal (-425 to -429 bp) or distal (-498 to -502 bp)
"CCAAT" box as a probe and nuclear extracts prepared
from COS-1 cells over-expressing NF-Y, mouse lungs, or
mtCC cells (Fig. 3A). In all three nuclear extracts, the same
pattern of specific protein-DNA shifted band was
obtained, although intensity varied, for both probes 1 and
2 (lane 1 and 6); the specific band was competed out by a
200-fold excess of cold probe (lane 2 and 7), but not by
an oligonucleotide having a mutation at the "CCAAT" site
(lane 3 and 8). Further, polyclonal anti-NF-Y antibody
specifically super-shifted the NF-Y-DNA complex with
both probes (lane 5 and 10), which was not seen with IgG
(lane 4 and 9) or anti- C/EBP antibody (data not shown)
as a negative control. These results demonstrate that NF-Y
binds to the two "CCAAT" binding elements located at -
425 to -429 and -498 to -502 bp in the Scgb3a1 gene pro-
moter.
In order to determine which NF-Y binding element is
responsible for Scgb3a1  gene transactivation, mutant
reporter plasmids were constructed by introducing muta-
tions singly or doubly into two of the "CCAAT" binding
sites in the -598 construct (Fig. 3B). Mutations introduced
Reporter analysis of the mouse Scgb3a1 gene Figure 1
Reporter analysis of the mouse Scgb3a1 gene. (A) Transient transfection of serial deletion luciferase reporter constructs 
into mtCC cells. Relative luciferase activity is shown as the mean ± SD based on the activity of pGL4 (shown as construct 0) as 
1 from three independent experiments, each carried out in duplicate. (B) Mouse Scgb3a1 promoter sequence of -600 bp to the 
transcription start site. Start points of the deletion constructs, -59, -91, -184, -273, and -598 are shown. NF-Y binding 
'CCAAT" sites are boxed. PU-boxes are shown in shaded boxes. A STAT binding site previously described for IL-4/13-induced 
increase of Scgb3a1 gene expression is shown in black box with white letters. GATA, HNF3β, and C/EBP binding sites identi-
fied by low stringency TF search analysis are indicated by over-bracket, overlined and underlined, respectively. CpG methyla-
tion sites are indicated in a gray box for complete methylation, and circled for unmethylated sites (see also Fig. 7 and Table 1).BMC Molecular Biology 2008, 9:5 http://www.biomedcentral.com/1471-2199/9/5
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were the same as those used for EMSA (see Fig. 3A). When
the proximal "CCAAT" binding site was mutated (Mut 1),
luciferase reporter activity with co-transfection of NF-Y
expression plasmid was reduced to approximately one-
third as compared to wild-type, whereas Mut 2 having the
distal "CCAAT" site mutated, displayed about one-half the
luciferase activity of wild-type. With both mutations
together, luciferase activity was further reduced to approx-
imately one-fourth of that of wild type. These results sug-
gest that the proximal NF-Y binding site may be slightly
more responsible, however, both NF-Y binding sites are
required for Scgb3a1 gene activation.
NF-Y is a dominant transcription factor over PU-box 
binding protein in the mouse Scgb3a1 gene promoter 
activity
The role of two PU-boxes (located at -99 to -105 bp and -
158 to -164 bp from the transcription start site, named
PU-box 1 and PU-box 2, respectively) in the mouse
Scgb3a1 gene promoter activity was examined by transfec-
tion analysis of mutant constructs in mtCC cells. Muta-
tions were introduced into the PU-boxes singly or doubly
in the -184 and -598 constructs, the latter containing two
NF-Y binding sites (Fig. 4A). In both -184 and -598 con-
structs, PU-box 1 and 2 individual mutants showed mark-
edly reduced reporter activities at the similar extent in
relative to their parent constructs, in which PU-box 2
appeared to be more responsible for the promoter activity.
The activity was further reduced to a basal level by both
mutations together. EMSA using mtCC nuclear extracts
demonstrated that oligonucleotide containing PU-box 1
or 2 produced the same specific DNA-protein band, which
was competed out by a cold probe, but not a mutated
probe (mPU1 or mPU2) (Fig. 4B). These results suggest
that both PU-boxes 1 and 2 may be required for transcrip-
tion of the mouse Scgb3a1 gene.
To determine which transcription factor between NF-Y
and PU-box binding protein is more critical for the regu-
lation of mouse Scgb3a1  gene, co-transfection experi-
ments were carried out in COS-1 cells using the construct
-598 and -598 PU-box1&2 double mutant with and with-
out NF-Y. While both constructs had very little reporter
activity without NF-Y (also see Fig. 4A), the promoter
activity was markedly increased by NF-Y over-expression
regardless of the presence of PU-box double mutation
(Fig. 4C). The importance of NF-Y in mouse Scgb3a1 gene
transcription was further demonstrated by co-transfection
into COS-1 cells of the -598 construct and an expression
plasmid for PU.1 (purine rich box-1)/Spi-1 (SFFV (spleen
focusforming virus) proviral integration site-1), one of the
PU box binding ETS family transcription factors [25,26],
although we do not know what ETS family member of
transcription factor is involved in mouse Scgb3a1  gene
transcription. In this case, Scgb3a1 promoter activity was
NF-Y comprised of all three subunits is required for mouse  Scgb3a1 gene transcription Figure 2
NF-Y comprised of all three subunits is required for 
mouse Scgb3a1 gene transcription. (A) Transient trans-
fection of serial deletion luciferase reporter constructs into 
COS-1 cells in the absence (control), or presence of NF-Y or 
its dominant negative form NFY(Am29). Relative luciferase 
activity is shown as the mean ± SD based on the activity of 
pGL4 (shown as construct 0) as 1 from three independent 
experiments, each carried out in duplicate. (B) -598 reporter 
construct was co-transfected with various combination of 
NF-Y subunits into COS-1 cells. Relative luciferase activity is 
shown as the mean ± SD based on the activity of construct -
598 without any NF-Y subunits as 1 from three independent 
experiments, each carried out in duplicate.BMC Molecular Biology 2008, 9:5 http://www.biomedcentral.com/1471-2199/9/5
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Analysis of NF-Y binding sites Figure 3
Analysis of NF-Y binding sites. (A) EMSA analysis of NF-Y binding sites. Proximal (Probe 1: -425 to -429 bp, lane 1–5) and 
distal (Probe 2: -498 to -502 bp, lane 6–10) "CCAAT" binding sites in the mouse Scgb3a1 gene promoter were incubated with 
nuclear extracts prepared from COS-1 cells over-expressing NF-Y, mouse lung and mtCC cells in the presence of no compet-
itor (lane 1, 6), 200-fold excess of own cold oligonucleotide as a competitor (lane 2, 7), 200-fold excess of mutant 1 or 2 as a 
competitor (lane 3 or 8, respectively), rabbit IgG as a control antibody (lane 4, 9), and polyclonal anti-NF-Y (anti-NF-YA and 
NF-YB combined) (lane 5, 10). NF-Y-DNA complex is indicated by an arrow, and NF-Y supershifted band is indicated by an 
arrowhead. Sequences for probe 1 and 2, and their mutants are shown at the bottom. These mutations were designed based 
on [37] and modification was added until complete abolishment of NF-Y binding was obtained. "CCAAT" sites are boxed and 
the mutated bases are underlined. (B) Transfection analysis of mutant constructs. COS-1 cells were co-transfected with -598 
wild-type or a mutant construct (Mut 1, Mut 2) in the presence or absence of NF-Y expression plasmid. An arrow indicates the 
direction of the "CCAAT" sequence. Relative luciferase activity is shown as the mean ± SD based on the activity of wild-type 
construct -598 in the absence of NF-Y as 1 from three independent experiments, each carried out in duplicate.BMC Molecular Biology 2008, 9:5 http://www.biomedcentral.com/1471-2199/9/5
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Analysis of PU-boxes Figure 4
Analysis of PU-boxes. (A) Transfection analysis of the constructs -184 and -598, and their respective PU-box 1 and 2 
mutants into mtCC cells. Mutations introduced into PU-box 1 and 2 are shown at the bottom. Relative luciferase activity is 
shown as the mean ± SD based on the activity of construct -598 without (w/o) mutation as 100 from three independent exper-
iments, each carried out in duplicate. (B) EMSA analysis of PU-box 1 (PU1) and 2 (PU2). EMSA was carried out using oligonu-
cleotide containing PU1 or 2 binding site as a probe (shown at the bottom) and nuclear extracts prepared from mtCC cells. 
Mutation was introduced into each binding site (mPU1, mPU2 in bold italics with underline) and was used as a competitor. 
Both PU1 and PU2 bound the same protein as shown by an arrow. (C) Transfection analysis of -598, and -598 PU-box 1 and 2 
mutants into COS-1 cells with and without NF-Y. (D) Cotransfection analysis of construct -598 and PU.1/Spi-1 expression 
plasmid into COS-1 cells in the presence and absence of NF-Y. Relative luciferase activity is shown as the mean ± SD based on 
the activity of the construct -598 without NF-Y as 1 from three independent experiments, each carried out in duplicate.BMC Molecular Biology 2008, 9:5 http://www.biomedcentral.com/1471-2199/9/5
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slightly increased by the addition of PU.1/Spi-1 expres-
sion plasmid both in the absence and presence of NF-Y,
however, again the effect of NF-Y on the promoter activity
was far more robust than the PU-box binding transcrip-
tion factor (Fig. 4D). These results suggest that NF-Y may
be a dominant transcription factor over PU-box binding
protein for mouse Scgb3a1 gene transcription. We there-
fore focused on NF-Y in further studies.
Analysis of NF-Y binding to its specific binding sites in the 
mouse Scgb3a1 gene promoter
In order to further demonstrate that NF-Y is a critical tran-
scription factor that binds to the promoter of Scgb3a1
gene and activates expression of the gene, chromatin
immunoprecipitation (ChIP) experiments were carried
out using mtCC cells that constitutively express SCGB3A1
[10,11], and NIH3T3 and mouse immortalized respira-
tory cell-derived MLE15 cells [27] that do not express
SCGB3A1. ChIP analysis demonstrated that NF-Y binds to
Scgb3a1 gene promoter in all three cell lines examined
regardless of SCGB3A1 expression (Fig. 5A and Table 1).
Further, when NF-YA shRNA was transfected to mtCC
cells, the amount of NF-YA protein was reduced to
approximately a half as compared to NF-YB subunit,
whose level stayed the same after NF-YA shRNA transfec-
tion (Fig. 5B). At the same time, SCGB3A1 mRNA levels
were reduced to approximately 60% (Fig. 5C). These
results together with the results described above, demon-
strate that NF-Y is necessary and perhaps sufficient for
Scgb3a1 gene expression through binding to the "CCAAT"
binding sites located in the mouse Scgb3a1  gene pro-
moter.
CpG methylation plays a role in the regulation of mouse 
Scgb3a1 gene
While NF-Y is a ubiquitous factor [20-22] and binds to the
mouse Scgb3a1 gene promoter, the expression in mouse is
mainly found in the trachea and lung [2,4,5]. In order to
understand the mechanism for tissue-specific expression
of SCG3A1, RT-PCR was first carried out to determine the
levels of expression of three NF-Y subunits, NF-YA, NF-YB,
and NF-YC, and SCGB3A1 in various mouse tissues
including brain, heart, kidney, liver, lung, skeletal muscle,
spleen and testis (Fig. 6). NF-YB and NF-YC were
expressed in all tissues examined at similar levels, whereas
expression of the NF-YA subunit varied depending on tis-
sue/cell types as previously described [21]: expression in
the brain, liver and skeletal muscle was very low or barely
detected as compared with other tissues. Interestingly,
SCGB3A1 was highly expressed only in the lung with very
weak expression detected in the heart. These results con-
firmed the ubiquitous pattern of NF-Y expression, which
does not correlate with SCGB3A1 expression.
NF-Y controls expression of Scgb3a1 gene Figure 5
NF-Y controls expression of Scgb3a1 gene. (A) ChIP 
analysis of mtCC, NIH3T3, and MLE15 cells for endogenous 
NF-Y binding. Antibodies used were NF-YA and IgG as a 
control. A sequence derived from the exon II of Scgb3a2, a 
homologous gene to Scgb3a1 was used as a reference gene. 
Illustration of the PCR strategy is shown at the bottom. 
Experiments were repeated twice and the same results were 
obtained. (B) Western blot analysis of NF-YA protein level 
after NF-YA shRNA transfection into mtCC cells. Experi-
ments were repeated twice and the same results were 
obtained. Representative western blot result is shown with 
the quantitated bar graph at lower panel. (C) Northern blot 
analysis of SCGB3A1 mRNA level after NF-YA shRNA trans-
fection into mtCC cells. Experiments were repeated twice 
and the same results were obtained. Representative north-
ern blot result is shown with the quantitated bar graph at 
lower panel.BMC Molecular Biology 2008, 9:5 http://www.biomedcentral.com/1471-2199/9/5
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In order to understand the tissue-specific expression of
SCGB3A1, the methylation pattern in the mouse Scgb3a1
promoter was examined. It is well known that DNA meth-
ylation plays an important role in tissue-specific gene
expression [28]. To this end, genomic DNA was subjected
to bisulfite modification, and the DNA fragment spanning
-600 bp upstream through +90 bp in the intron 1 of the
mouse Scgb3a1 gene was PCR amplified, followed by a
direct DNA sequencing of the PCR fragment to determine
the site of CpG methylation in the promoter and around
the transcription start site of the gene. This modification
converts non-methylated cytosine to uracil but does not
affect 5-methyl cytosine. In the region between +90 to -
600 bp of the mouse Scgb3a1 gene, nine CpG methylation
sites were found, all of which were located between NF-Y
binding sites and the transcription start site (Fig. 1B). Of
nine, seven methylation sites located at the most 5' were
always methylated regardless of tissues/cell lines exam-
ined, whereas two methylation sites closest to the tran-
scription start site were partially or totally unmethylated
in lung or mtCC cells, respectively (Fig. 7 and Table 1).
When 28 individual clones obtained from PCR products
of bisulfite modified lung DNAs were subjected to
sequencing, 10 were found to have the two CpG sites clos-
est to the transcription start site methylated while 18 were
unmethylated. These results suggest that lung DNAs con-
sist of a mixture of methylated and unmethylated CpGs.
Note that direct sequencing of DNAs from lung, mtCC
and NIH3T3 cells without bisulfite modification did not
demonstrate any mutations anywhere within +90 to -600-
bp region. Interestingly, lung and mtCC were the only tis-
sues/cells that exhibited high level of SCGB3A1 expres-
sion. Together with the results obtained by ChIP analysis,
in which all mtCC, NIH3T3, and MLE15 cells have bound
NF-Y at its specific binding sites of the mouse Scgb3a1 pro-
moter regardless of SCGB3A1 expression, and that NF-Y is
ubiquitously expressed in all tissues/cells examined, the
bisulfite sequencing results demonstrate that two methyl-
ation sites closest to the transcription start site in the
Scgb3a1 promoter may be responsible for tissue-specific
expression of SCGB3A1.
Lastly, in order to examine whether CpG methylation
affects binding of DNA-binding proteins, we performed
EMSA using an oligonucleotide having the proximal or
distal CpG methylated as compared with unmethylated
oligonucleotide (Fig. 8). When CpG was methylated, an
additional band(s) was observed for both oligonucle-
otides flanking proximal or distal CpG using nuclear
extracts prepared from mtCC and mouse hepatoma-
derived Hepa1 cells. Since the shifted band is at different
position between two oligonucleotides, they may repre-
sent different DNA-binding proteins. These results suggest
RT-PCR analysis for the expression of NF-YA, NF-YB, NF- YC, and SCGB3A1 Figure 6
RT-PCR analysis for the expression of NF-YA, NF-
YB, NF-YC, and SCGB3A1. RNAs isolated from various 
organs of adult mouse were subjected to RT-PCR. S. Muscle; 
skeletal muscle. Note that high SCGB3A1 expression is 
found only in lung.
Table 1: Correlation between Scgb3a1 promoter methylation and gene expression in various mouse tissues/cells
Mouse tissues/cells Proximal 2 CpGs Methylation SCGB3A1 expression
Brain Yes No
Heart Yes Very low
Kidney Yes No
Liver Yes No
Lung Methylated + Unmethylated High
Skeletal Muscle Yes No
Spleen Yes No
Testis Yes No
mtCC Unmethylated High
MLE 15 Yes No
Hepa 1 Yes No
NIH3T3 Yes NoBMC Molecular Biology 2008, 9:5 http://www.biomedcentral.com/1471-2199/9/5
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DNA methylation analysis Figure 7
DNA methylation analysis. Distal and proximal CpG sites of the mouse Scgb3a1 gene promoter were subjected to direct 
DNA sequencing after bisulfite treatment and PCR amplification of DNAs isolated from mtCC, NIH3T3 and mouse lungs. 
Sequence containing CpG site is shown at the top, and CpG site is boxed. Cytosine residues are underlined. If these cytosine 
residues are unmethylated, they appear as thymine after bisulfite treatment (upper panel; mtCC unmethylated, shown by a 
black arrow). The cytosine residue that is methylated stays as cytosine even after bisulfite treatment (middle panel; NIH3T3 
methylated, shown by a red arrow). Lung DNA shows both T and C residues due to a mixture of cell types of methylated and 
unmethylated (bottom panel; Lung mixed, shown by a black and red arrow).BMC Molecular Biology 2008, 9:5 http://www.biomedcentral.com/1471-2199/9/5
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that CpG methylation affects the binding of DNA-binding
proteins.
Discussion
We report here for the first time that a ubiquitous tran-
scription factor NF-Y is important for regulation of the
mouse Scgb3a1 gene, while DNA methylation appears to
be associated with tissue-specific expression of the gene.
NF-Y recognizes a "CCAAT" penta-nucleotide that can be
found at every 500 bp in random genomic DNAs based on
mathematical calculation. With additional high strin-
gency, in which the "CCAAT" box is expanded to a 9-
nucleotide element as (G/A)(G/A)CCAAT(C/G)(A/G)(G/
C) [20], this sequence appears every 16 kbp in frequency.
A "CCAAT" box is found in the vicinity of promoter region
(between -60 and -100 bp of the major start site in both
orientations) with significant high frequency (30%), sug-
gesting that NF-Y may play a pivotal role in controlling
expression of many genes [29]. In the current study,
CCAAT boxes were located further upstream (-425 to -429
bp and -498 to -502 bp), away from the vicinity of Scgb3a1
gene transcription start site.
Transfection analysis in COS-1 cells revealed that the -59
and -273 constructs increased reporter activity two-fold in
an NF-Y dependent manner (see Fig. 2A). However, no
"CCAAT" binding sequence was found between -59 bp
and the transcription start site, nor did EMSA reveal any
NF-Y binding in this region (data not shown). While an
exact "CCAAT" sequence is required for NF-Y binding,
"CCACT" sequence was reported to similarly function as
the NF-Y binding site in regulation of Oncoprotein18
gene [30]. A low stringency survey revealed the presence of
two "CCACT" sequences in the Scgb3a1 gene promoter at
-44 to -48 bp and -113 to -117 bp, however, neither
bound NF-Y as determined by EMSA (data not shown).
Further, when NFYAm29, a dominant negative form of
NF-YA was co-transfected with the constructs -598, an
approximately two-fold higher luciferase activity as com-
pared to control remained even though a heterotrimer
with NF-Yam29 cannot bind DNA (Fig. 2A) [24]. Moreo-
ver, mutation of the two NF-Y binding sites did not com-
pletely abolish NF-Y activation of the -598 construct
luciferase activity (Fig. 3B). The exact reason for these phe-
nomena is not known. However, it has been established
that NF-Y interacts with TATA-binding protein (TBP) [31],
TFIID [31], and coactivators such as p300 [32] and P/CAF
[33] that modify gene expression. The interaction of NF-Y
with these factors could stabilize basic transcription
machinery and/or its association with DNA, which in turn
results in a slight increase in Scgb3a1 reporter activity with
co-transfection of constructs -598 and NF-YAm29, and/or
the constructs -59/-273 and NF-Y expression plasmid.
Note that in these reporter assays, three expression con-
structs, NF-YA, NF-YB, and NF-YC were simultaneously
co-transfected along with a reporter construct. The fact
that only cells that have taken up all four plasmids can
produce a complete form of NF-Y that can activate the
promoter suggests that the 20-fold increase of Scgb3a1
promoter activity obtained in this co-transfection assay
system may represent only a fraction of naturally occur-
ring NF-Y regulated Scgb3a1 expression.
The importance of NF-Y, in particular the NF-YA subunit
in mouse Scgb3a1 gene expression was demonstrated by
reporter activities using a various combination of NF-Y
subunits and reduced SCGB3A1 mRNA expression by NF-
YA shRNA. In the latter, both NF-YA protein and
SCGB3A1 mRNA levels were suppressed at similar levels
of approximately 50–60% of the control. This incomplete
suppression may be due to the fact that NF-Y is a ubiqui-
tous transcription factor and regulates many genes includ-
ing housekeeping genes and those involved in cell cycle
control, that account for approximately 20% of all genes
EMSA with methylated CpG oligunucleotides Figure 8
EMSA with methylated CpG oligunucleotides. EMSA 
was carried out using nuclear extracts prepared from mtCC 
or Hepa 1 cells and oligonucleotides containing proximal or 
distal CpG site methylated (Me +) or unmethylated (Me -). 
Oligonucleotide sequences are shown at the bottom with 
methylated C underlined in boldface. Shifted bands only seen 
with methylated CpG oligonucleotide are shown by open 
arrowhead for proximal or asterisk for distal CpG region.BMC Molecular Biology 2008, 9:5 http://www.biomedcentral.com/1471-2199/9/5
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[20,22,34]. Thus, complete suppression of NF-Y expres-
sion may likely result in suppression of cell proliferation
and cell death. Indeed, a knockout mouse for NF-YA is
embryonic lethal, and embryonic fibroblasts prepared
from this mouse demonstrate halted cell proliferation and
DNA synthesis [35].
An important factor controlling tissue-specific expression
of genes is CpG methylation [28]. This may particularly
play a role in suppressing expression of NF-Y-responsive
genes in many tissues since NF-Y is ubiquitously
expressed [20-22] and is responsible for recruitment of
RNA polymerase II [36]. However, the possibility exists
that NF-Y may cooperate with another transcription fac-
tor(s), which could render expression of genes tissue and/
or stage-specific. For instance, NF-Y and C/EBPα interact
with each other and synergistically activate the mouse
amelogenin gene, which contributes to physiological reg-
ulation during amelogenesis [37]. Whether this could be
the case in the regulation of mouse Scgb3a1 gene expres-
sion remains to be determined.
DNA methylation is known to suppress gene expression
through two basic mechanisms [38,39]; first, methylation
of cytosine bases inhibit association between DNA-bind-
ing factors and their cognate DNA recognition sequences,
resulting in direct inhibition of transcriptional activation.
Second, proteins that recognize methyl-CpG such as
methyl-CpG-binding proteins elicit repressive potential of
methylated DNA by recruiting co-repressor molecules to
silence gene transcription and to modify surrounding
chromatin, including histone modification. In the case of
the mouse Scgb3a1  gene, the second mechanism most
likely plays a role in silencing expression of the gene since
two CpGs are located closest to the transcription start site,
which is 3–400 bp downstream of the NF-Y binding sites.
These two CpGs in the mouse Scgb3a1 gene promoter are
partially or completely unmethylated in mouse lung and
mtCC cells, respectively. The partial methylation observed
in the lung is the result of a mixture of methylated and
unmethylated CpGs at approximately a 1:2 ratio.
Although we do not have a proof, the methylated CpGs
might be at least partially derived from non-epithelial
cells such as mesenchymal cells that are contained in
whole lung from which genomic DNA for methylation
analysis was prepared. We found that the two CpGs were
totally methylated when embryonic lung mesenchymal
cells that do not express SCGB3A1 were separately pre-
pared from epithelial cells and subjected to sequencing
(Tomita and Kimura, unpublished results). SCGB3A1 is
known to be expressed only in the airway epithelium [5].
However, very low SCGB3A1 expression was observed in
the heart even though the two CpGs closest to the tran-
scription start site were methylated. The reason for this
difference is not known. A small percentage of these CpGs
might be unmethylated in a specific part of the heart and
not abundant enough to be detected particularly using
mRNA prepared from whole heart. In this regard, the
expression site in the heart is not known. Alternatively,
another transcription factor(s) enriched in the heart
might be responsible for the low SCGB3A1 expression in
this tissue. EMSA using methylated CpG oligonucleotides
revealed the presence of additional shifted bands as com-
pared to unmethylated oligonucleotides. This could be
due to binding of one of the methyl-CpG-binding pro-
teins [38,40] or other DNA-binding proteins (transcrip-
tion factors or co-factors) to these sites. We do not know
which methyl-CpG-binding protein or DNA-binding pro-
tein is responsible for the new band, however the results
at least suggest that CpG methylation affects binding of
DNA-binding proteins within the region around proximal
and distal CpGs in the mouse Scgb3a1 gene promoter. Pre-
viously we reported that a STAT binding element located
at -201- to -209 bp of the mouse Scgb3a1 gene promoter
is responsible for the IL-3/14-induced increase of Scgb3a1
gene expression in mtCC and mouse embryo lung pri-
mary cells [11]. This STAT element is located to close to
the 3' most methylated CpG. Whether any changes in
methylation status in this CpG under IL-3/14 induction
remains to be determined.
Lastly, in the human SCGB3A1 gene promoter, 138 poten-
tial methylation CpG sites are found within 1,500 bp of
the promoter region [1]. High frequency of methylation
of these CpGs is associated with loss of SCGB3A1 expres-
sion in many human cancers [6-8]. In contrast, there are
only 9 CpGs within 600 bp of the mouse Scgb3a1 gene
promoter. This remarkable species difference in CpG
islands can be explained by little significant homology in
DNA sequences between the human and mouse gene pro-
moters, suggesting that mouse Scgb3a1  and human
SCGB3A1 may be under different regulation. This could
explain the different patterns of SCGB3A1 expression
between these two species. Whether the difference in gene
regulation has any implication in functional role of
SCGB3A1 between mouse and human requires additional
studies.
Conclusion
A ubiquitous transcription factor, NF-Y appears to be a
potential potent regulator of mouse Scgb3a1 gene expres-
sion through binding to two "CCAAT" boxes located at -
425 to -429, and -498 to -502 bp in the Scgb3a1 gene pro-
moter. Tissue-specific expression of SCGB3A1 may be due
in part to methylation of the two CpG sites closest to the
transcription start site of the gene.BMC Molecular Biology 2008, 9:5 http://www.biomedcentral.com/1471-2199/9/5
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Methods
Materials
Normal rabbit IgG (sc-2027), anti-NF-YA (sc-10779X)
and anti-NF-YB (sc-13045) antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). All
restriction endonucleases were obtained from New Eng-
land Biolabs (Ipswich, MA).
Plasmid construction
Serial Scgb3a1  gene promoter deletion mutants were
constructed with PCR using mouse genomic DNA and
the following primers: forward primer for -59 construct
5'-CAAACTAGTTCCCAGGAGGGTGAGGTTCCAC-3', -
91 construct 5'-TAAGCTAGCCCTTTCTGCCTGT-
TAGCTGAGCAAAC-3', -184 construct 5'-CACACTAGT-
TCAGGAGACCCTGCCAAGAG-3', -273 construct 5'-
AGGACTAGTCAGACCACATTATCAAGGTGTAGG-3',
and -598 construct 5'-CCCACTAGTCATTAGCAGCTAC-
CTGTGGCCCAAC-3', and a common reverse primer 5'-
AGAGGATCCCAGGACCTATAAGACAATCTTCC-3'.
PCR products were double-digested with Spe I (Nhe I
for -91 construct) and Bam HI, and cloned into the Nhe
I – Bgl II site of the pGL4.11 vector (Promega, Madison,
WI). These reporter constructs contained +24 bp of the
5' UTR of the SCGB3A1 mRNA sequence.
For construction of expression plasmids, total RNAs isolated
from mouse embryonic lungs (embryonic day 16.5) by
using TRIZOL (Invitrogen, Carlsbad, CA) were first treated
with DNase I (Ambion, Austin, TX) and subjected to cDNA
synthesis using Superscript II reverse transcriptase (Invitro-
gen). PCR reactions were carried out using the following
primers: 5'-TTAGCGGCCGCATGGAGCAGTATACGACAAA
CAGCAATAG-3' and 5'-TAATCTAGATTAGGAAACTCGGAT-
GATCTGTGTCATGG-3' for NF-YA, 5'-TAAGGTACCTTA-
CATGACAATGGACGGCGACAGCTC-3' and 5'-TAATCTAG
ATCATGAAAACTGAATTTGCTGGACACCAG-3' for NF-
YB, 5'-TAAGCGGCCGCACCATGTCCACAGAAGGAGGG
TTTGG-3' and 5'-TTATCTAGAGCCCTCAGTCTCCAGT-
CACCTGG-3' for NF-YC, and 5'-TTAGCGGCCGCATGTT-
ACAGGCGTGCAAAATGGAAGG-3' and 5'-TTATCTAGAC
GATCAGTGGGGCGGGAGG-3' for PU.1/Spi-1. PCR
products were subcloned into the Not I – Xba I (NF-YA,
NF-YC and Spi-1) or Kpn I – Xba I sites (NF-YB) of
pcDNA3.1 vector (Invitrogen). The NF-Y binding site and
PU-box mutations were generated by site-directed muta-
genesis kit (Stratagene, La Jolla, CA). All plasmid
sequences were confirmed by DNA sequence analyses
(Beckman Coulter, model CEQ-200XL, Fullerton, CA).
Reporter gene assays
COS-1 and mtCC cells were seeded in 24-well tissue cul-
ture plates in DMEM with high glucose and L-glutamine
(Invitrogen), supplemented with 10% FBS. A transfection
cocktail contained 20 µl serum-free DMEM, 1 µl Fugene 6
(Roche Applied Science, Indianapolis, IN), 250 ng
reporter construct, and 5 ng pGL4.74 Renilla luciferase
vector (Promega) as an internal control, and whenever
necessary, a various combination of three NF-Y expression
plasmids (16.6 ng each, a total amount adjusted to 50 ng
with a control vector). In order to have all plasmids trans-
fected into a cell, the amount of each expression plasmid
used were kept small and transfection was carried out
using cells at 50% confluency. Cells were washed with PBS
48 h after transfection, and lysed in passive lysis buffer
(Promega). Luciferase activity was determined using a
luminometer (Pharmingen, model monolight 3010) with
Dual-Luciferase Reporter Assay System (Promega). All
reporter assays were carried out at least three times, each
in duplicate, and the results were expressed as the mean ±
SD.
For shRNA experiments, synthetic oligonucleotide
designed to generate RNAi for mouse NF-YA (Invitrogen,
Mmi515428) was inserted into a linearized vector
pcDNA6.2-GW/miR (Invitrogen). mtCC cells transfected
with Mmi515428/pcDNA6.2-GW/miR or control
pcDNA6.2-GW/miR were maintained in media contain-
ing 2 µg/ml blasticidin (Invitrogen).
Nuclear extracts
Nuclear extracts were prepared from COS-1 cells trans-
fected with NF-Y expression plasmids, mouse lungs and
mtCC cells [41]. In the case of COS-1 cells, 1 ml of serum-
free DMEM containing expression constructs (NF-YA, NF-
YB, and NF-YC, 7 µg each) was mixed with 50 µl of Fugene
HD (Roche Applied Science, Indianapolis, IN), which
after 15 min incubation, added to COS-1 cells that were
grown to 50–80% confluency in 150-mm dish. The media
was changed 8 h after transfection, and 48 h after the
media change, cells were washed and harvested in cold
PBS. Cell suspension was centrifuged for 5 min at 1,000
rpm and the pellet was resuspended in 2 ml Buffer A (10
mM HEPES, pH 7.6, 15 mM KCl, 2 mM MgCl2, 0.1 mM
EDTA, 1 mM DTT, 0.5 mM PMSF). After centrifugation at
2,500 rpm for 3 min, cell pellet was suspended in Buffer B
(Buffer A + 0.2% IGEPAL), followed by re-centrifugation
for 3 min at 2,500 rpm. Mouse lungs were homogenized
using a dounce homogenizer in Sucrose buffer (250 mM
sucrose, 10 mM HEPES, pH 7.6, 15 mM KCl, 2 mM
MgCl2, 0.5 M EDTA, 1 mM DTT, 0.5 mM PMSF), and cen-
trifuged for 3 min at 2,500 rpm. The nuclear pellets thus
obtained were washed with Sucrose buffer mixed with
Extraction buffer (50 mM HEPES, pH 7.9, 400 mM KCl,
0.1 mM EDTA, 10% Glycerol, 0.5 mM PMSF), and rotated
in cold room for 30 min. Finally, the nuclear extract was
obtained by centrifugation, and protein concentration
was adjusted at 2 mg/ml by using Bradford protein assay
(Bio-Rad Laboratories, Hercules, CA) with BSA as a stand-
ard.BMC Molecular Biology 2008, 9:5 http://www.biomedcentral.com/1471-2199/9/5
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Electrophoretic mobility shift assays (EMSA)
Oligonucleotides were radio-labeled with [γ-32P]ATP
(PerkinElmer, Wellesley, MA) and T4 polynucleotide
kinase (New England Biolabs). Nuclear extract (1 µl) was
diluted in Binding buffer (0.1 µg/µl polydI-dC, 10 mM
Tris, pH 8.0, 1 mM DTT, 80 mM KCl, 20% Glycerol, 0.04
µg/µl BSA) and incubated for 15 min at room temperature
with radio labeled probe in the presence or absence of
cold oligonucleotide as a competitor. For supershift anal-
ysis, the mixture was incubated with 1 µl of antibody solu-
tion for additional 15 min at room temperature. DNA-
protein complexes were electrophoresed on a 4% polyacr-
ylamide gel using 0.5× TBE buffer, and were visualized by
exposing to phosphoimager screen (Storm 840, Amer-
sham Biosciences, Piscataway, NJ).
Chromatin immunoprecipitation (ChIP) assays
DNA was isolated from mtCC, NIH3T3, and MLE15 cells
that were fixed with 1% formaldehyde, followed by soni-
cation. MLE15 was grown in HITES (RPMI-1640 supple-
mented with insulin, transferrin, sodium selenite [Sigma,
St. Louis, MO], 10 mM hydrocortisone [Sigma], 10 mM γ-
estradiol [Sigma], 10 mM HEPES [Invitrogen], and
2%FCS). Endogenous NF-Y together with fragmented
DNAs was pulled down by anti-NF-YA or rabbit IgG as
control. After reverse cross-linking, the Scgb3a1 promoter
region containing the NF-Y binding site (200 bp) and a
region derived from Scgb3a2 intron 1 + exon 2 as a refer-
ence (219 bp) were PCR amplified. PCR primers used
were as follows: 5'-GCTATTAGGCATTCCTTTCTGGCTC-
3' and 5'-CCACGGGCGATTATGTAGGTTC-3' for amplifi-
cation of the NF-Y binding site, and 5'-TCTTCAGTCCTGT-
CACCAGATGTTCTAC-3' and 5'-
CGAGAGGGATGGGATGGAGTCTTAG-3' for the refer-
ence. Sample solution was mixed with each primer set and
Taq polymerase, followed by PCR reaction of 25 cycles
with 94°C denaturation, 15 sec, 56.5°C annealing, 15 sec,
and 72°C extension, 30 sec.
RT-PCR analysis
RNAs isolated from various organs of adult mouse and
various mouse cell lines were subjected to RT-PCR analy-
sis. PCR was carried out after cDNA synthesis using the
following primers: 5'-CTCTACAGATCCCAGGCAGC-3'
and 5'-CTGGAGCCTCTGATTGGGT-3' for NF-YA, 5'-
TAGCTGGGAGGCATCTGTG-3' and 5'-AGGATCCAC-
CACCTTTTTGA-3' for NF-YB, 5'-TTTCTTCCATGACTCT-
GGGC-3' and 5'-GCTGCTTTCTTCGCTGGA-3' for NF-YC,
and 5'-GATGGCCAAGTGGCTTAATG-3' and 5'-TCTGT-
GTGGCTCTGCTCAGT-3' for SCGB3A1. PCR condition
used was 94°C, 2 min, followed by 30 cycles of 94°C, 15
sec, 55°C, 15 sec, and 68°C, 30 sec.
Northern blot
Total RNA (3 µg) isolated from mtCC cells was electro-
phoresed on 1% agarose gel containing 0.22 M formalde-
hyde and transferred onto nitrocellulose membrane
(Immobilon-Ny+, Millipore, Billerica, MA). Filters were
hybridized with mouse SCGB3A1 and ribosomal protein
B36 (loading control) as a probe. Hybridization was per-
formed in Perfect Hybridization solution (Amersham Bio-
sciences) at 68°C overnight. The membrane was washed
twice with 2 × SSC containing 0.1% SDS at 68°C for 30
min, followed by exposure to phosphoimager screen.
Data processing was carried out using ImageQuant TL
2005 software (Amersham Biosciences).
Western blot
Nuclear extracts (3 µg) obtained from mtCC cells were run
on 10% SDS-polyacrylamide gels, and proteins trans-
ferred onto PVDF membrane (Hydond-P, Amersham Bio-
sciences). The membrane was gently shaken with PBS
containing 5% skim milk at 4°C overnight, followed by
incubation with anti-NF-YA or NF-YB antibody diluted in
PBS containing 1% Tween 20 (PBST). After washing three
times with PBST, the membrane was incubated with
horseradish peroxidase conjugated anti-rabbit IgG
(NA9340V, Amersham Biosciences) followed by further
three times wash with PBST. Signals were directly detected
and quantified using chemiluminescence reaction
(Immobilon Western, Millipore) with CCD camera sys-
tem and equipped software (Alpha Innotech Fluor Chem
HD2, San Leandro, CA).
DNA methylation analysis
Genomic DNAs were isolated based on simplified proce-
dure [42] from various tissues and cultured cells. Isolated
DNAs were overnight digested with Bam HI at 37°C, eth-
anol precipitated after phenol-chloroform extraction and
pellets were dissolved in TE buffer. EZ DNA methylation
kit (Zymo Research, CA) was used to generate bisulfite
treated DNA. Five hundred ng of DNA was incubated with
bisulfite at 50°C for 16 h, and the product was purified
and desulphonated through a spin-column. This proce-
dure converts all non-methylated cytosine to uracil but
does not affect 5-methyl cytosine. Two µl of final elution
from the spin-column was used as template for two differ-
ent PCRs with a primer set, 5'-GTGGTTTTTGGAAGAAAG-
GTTTAGTATTTGAGTTTAGG-3' and
TACTAAACCCCCAAAAAAACTCACCAAAAATCAC-3' for
proximal  Scgb3a1  promoter region (343 bp), and 5'-
GAGAGATTTAGAGTTTTTGGGATTTGTTGATTTAT-3' and
5'-CCCACCTCAATCCTAAAAATTTCCTCTTAAC-3' for dis-
tal Scgb3a1 promoter region (279 bp). Both PCR reactions
were carried out at the same conditions; 94°C, 2 min, fol-
lowed by 40 cycles of 94°C, 15 sec, 52.8°C, 15 sec, and
68°C, 30 sec. All PCR products were subjected to 2% aga-
rose gel electrophoresis, and each band was excised andBMC Molecular Biology 2008, 9:5 http://www.biomedcentral.com/1471-2199/9/5
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purified (gel extraction kit, Qiagen, Valencia, CA) for sub-
sequent direct sequencing analysis to identify cytosine res-
idues, but not thymine (uracil), that was the result of
resistance to bisulfite reaction due to methylation. In
some cases, PCR products were subcloned into pGEM-T
easy vector (Promega) and individual clones were sub-
jected to sequencing analysis. For confirmation of non-
bisulfite treated genomic DNA sequence, PCR was carried
out using the following primer sets: 5'-CAGAAAAATGT-
CACAGCCCCTC-3' and 5'-CCAACTTCCTCTTATGGT-
CAGTGGAC-3' to obtain 543-bp fragment of the distal
Scgb3a1 promoter region containing the two CCAAT sites
and 5'-CTTCCAGACCCAGAACCTACATAATC-3' and 5'-
AGAGTCACTGAGCAGAGCCACAC-3' to obtain 471-bp
fragment of the proximal Scgb3a1 promoter region. PCR
condition used was 94°C, 2 min, followed by 30 cycles of
94°C, 15 sec, 58°C, 15 sec, and 68°C, 60 sec.
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